Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABX464 in moderate to severe active ulcerative colitis
NCT03093259Phase 2Completed
- Sponsor
- Abivax
- Start
- Nov 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of obefazimod in ulcerative colitis (UC), sponsored by Abivax. Started Nov 2017; status: completed.
02
Drugs
obefazimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03093259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03093259.